[Congressional Record Volume 169, Number 151 (Tuesday, September 19, 2023)]
[Senate]
[Page S4603]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]

  SA 1256. Mr. LANKFORD submitted an amendment intended to be proposed 
to amendment SA 1092 proposed by Mrs. Murray (for herself and Ms. 
Collins) to the bill H.R. 4366, making appropriations for military 
construction, the Department of Veterans Affairs, and related agencies 
for the fiscal year ending September 30, 2024, and for other purposes; 
which was ordered to lie on the table; as follows:

       At the appropriate place in title VII of division B, insert 
     the following:
       Sec. 7__. (a) The modifications approved by the Food and 
     Drug Administration on January 3, 2023, to the risk 
     evaluation and mitigation strategy under section 505-1 of the 
     Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1) for 
     mifepristone shall have no force or effect.
       (b) None of the funds made available by this Act may be 
     used to--
       (1) establish, implement, or enforce any provision of a 
     risk evaluation and mitigation strategy under section 505-1 
     of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1) 
     for mifepristone that is substantially similar to any of the 
     modifications nullified by subsection (a); or
       (2) exercise discretion to not enforce any provision of a 
     risk evaluation and mitigation strategy under such section 
     505-1 for mifepristone.
                                 ______